SRC and neoplasm: Knockdown of FGFR4 or treatment with TKI258, an FGFR inhibitor, markedly inhibits Src activation, which results in the loss of metastatic potential, epithelial–mesenchymal transition (EMT) induction, and tumor growth in vivo [28,29].